Literature DB >> 1484947

Use of prednisolone in the treatment of HIV-positive tuberculosis patients.

A M Elliott1, B Halwiindi, A Bagshawe, R J Hayes, N Luo, J O Pobee, K P McAdam.   

Abstract

Corticosteroids are beneficial in the treatment of some forms of tuberculosis, but their role in TB affecting HIV-positive patients is not clear. During a cohort study of tuberculosis patients in Lusaka, Zambia, prednisolone was prescribed for specific indications. Six of 47 (13 per cent) of patients who received prednisolone early in treatment developed herpes zoster, compared with 2 of 118 (2 per cent) of those who did not. Three patients who received prednisolone developed Kaposi's sarcoma, compared with none who did not. At 2 months patients who had received prednisolone showed a greater improvement in generalized lymphadenopathy and cough. Controlled studies of the risks and benefits of administration of corticosteroids to HIV-positive TB patients are urgently needed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484947

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  13 in total

1.  Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients.

Authors:  J G Hakim; I Ternouth; E Mushangi; S Siziya; V Robertson; A Malin
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

Review 2.  Tuberculous pericarditis and AIDS: case reports and review.

Authors:  A Mastroianni; O Coronado; F Chiodo
Journal:  Eur J Epidemiol       Date:  1997-10       Impact factor: 8.082

Review 3.  Management of active tuberculosis in adults with HIV.

Authors:  Graeme Meintjes; James C M Brust; James Nuttall; Gary Maartens
Journal:  Lancet HIV       Date:  2019-07       Impact factor: 12.767

Review 4.  Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.

Authors:  Stephen D Lawn; Graeme Meintjes
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

Review 5.  Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa.

Authors:  Bongani M Mayosi
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

6.  Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.

Authors:  Bongani M Mayosi; Mpiko Ntsekhe; Jackie Bosch; Shaheen Pandie; Hyejung Jung; Freedom Gumedze; Janice Pogue; Lehana Thabane; Marek Smieja; Veronica Francis; Laura Joldersma; Kandithalal M Thomas; Baby Thomas; Abolade A Awotedu; Nombulelo P Magula; Datshana P Naidoo; Albertino Damasceno; Alfred Chitsa Banda; Basil Brown; Pravin Manga; Bruce Kirenga; Charles Mondo; Phindile Mntla; Jacob M Tsitsi; Ferande Peters; Mohammed R Essop; James B W Russell; James Hakim; Jonathan Matenga; Ayub F Barasa; Mahmoud U Sani; Taiwo Olunuga; Okechukwu Ogah; Victor Ansa; Akinyemi Aje; Solomon Danbauchi; Dike Ojji; Salim Yusuf
Journal:  N Engl J Med       Date:  2014-09-01       Impact factor: 91.245

Review 7.  Management of individuals requiring antiretroviral therapy and TB treatment.

Authors:  Karen Cohen; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2010-01       Impact factor: 4.283

8.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Robert J Wilkinson; Chelsea Morroni; Dominique J Pepper; Kevin Rebe; Molebogeng X Rangaka; Tolu Oni; Gary Maartens
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

9.  Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance.

Authors:  Graeme Meintjes; Molebogeng X Rangaka; Gary Maartens; Kevin Rebe; Chelsea Morroni; Dominique J Pepper; Katalin A Wilkinson; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

Review 10.  Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management.

Authors:  Devesh J Dhasmana; Keertan Dheda; Pernille Ravn; Robert J Wilkinson; Graeme Meintjes
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.